Moderna Q3 net loss $3.6B on $1.8B revenue; guides 2024 sales ~$4B, aims for 2026 breakeven

Moderna, Inc.

2023-Q3 EPS reported -$12.89 revenue$4,037,000,000

Q3 revenues $1.8B, down 44% YoY; net loss $3.6B vs net income $1.0B; diluted EPS -$9.53.
Non-cash charges of $3.1B: $1.3B inventory write-downs, $0.5B contract manufacturing wind-down, $1.7B tax valuation allowance.
2023 product sales guidance at least $6B; 2024 sales projected ~$4B; expects breakeven in 2026.
COVID-19 U.S. market share rose to 45% (from 36%); RSV vaccine BLA filed with FDA, launch expected 2024.
Cash and investments $12.8B; plans to fund without raising equity.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

Moderna, Inc. reported third quarter ended September 30, 2023 results: revenue $1.8 billion, net income $3.6 billion. Guidance reaffirmed.

Period: third quarter ended September 30, 2023
Revenue: $1.8 billion
Net income: $3.6 billion
Guidance: reaffirmed
Result: reported results

Exact text from the filing

Moderna Reports Third Quarter 2023 Financial Results and Provides Business Updates Third quarter 2023 revenues of $1.8 billion; Company expects 2023 revenues of at least $6 billion

View on SEC.gov

Browse all earnings releases →

Moderna, Inc. filing history →

Source: SEC EDGAR

accession 0001682852-23-000038

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.